iXCells Biotechnologies, a leading provider of human cell-based solutions and custom iPSC services, has announced the delivery of over 500 characterised induced pluripotent stem cell (iPSC) lines as part of a multi-year collaboration with a global biotechnology company.
The collaboration leverages iXCells’ iPSCore platform, which enables the large-scale generation of well-characterised patient-derived iPSC lines, to support the discovery and development of novel therapeutics.
The platform supports drug discovery by enabling the creation, characterisation and delivery of validated iPSC lines derived from diverse patient cohorts.
iPSCore is delivering nearly 200 lines per month, with a reprogramming success rate exceeding 98%, and built-in cell banking at each stage to ensure continuity and mitigate risk.
This scale allows researchers to study large patient cohorts, capturing population-level genetic diversity and minimizing background variance, which is critical for understanding complex diseases such as neurodegenerative disorders, oncology, cardiac disorders, or toxicology screening.
To date, iXCells has delivered more than 500 characterised patient-derived iPSC lines under the collaboration, with more than 700 additional lines in development, demonstrating the scalability and efficiency of the iPSCore platform.
The collaboration demonstrates iXCells’ ability to deliver iPSC reprogramming at industrial scale, enabling high-throughput production of large volumes of patient-derived lines while maintaining quality, reproducibility, and consistency.
Further projects as part of the collaboration will expand the scale of the platform, including for differentiated cell types and disease-relevant models.
The generation of validated iPSC lines using iPSCore is particularly meaningful in complex therapeutic areas where understanding patient diversity and disease biology is crucial.
By enabling scalable access to high-quality, cohort-based iPSC models, iXCells is supporting researchers to generate comprehensive, population-relevant data sets, accelerating target identification and optimizing therapeutic strategies.
